On the Use of Cariprazine in Patients with Bipolar Affective Disorder: the View of a Psychoendocrinologist

References

1. Биполярное аффективное расстройство: диагностика и терапия / Под ред. С.Н.Мосолова. – М.: МЕДпресс-информ. – 2008. – 384 с.
2. Костюкова Е. Расширение показаний антипсихотиков второго поколения: от шизофрении к биполярному расстройству // Современная терапия психических расстройств. – 2020. – №3. – С. 29-37.
3. Hilty D.M., Leamon M.H., Lim R.F. et al. A review of bipolar disorder in adults // Psychiatry (Edgmont). – 2006. – 3 (9). – Р. 43-55.
4. Kessler R.C., Bergland P., Demler O. et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication // Arch. Gen. Psychiatry. – 2005. – 62. – Р. 593-602.
5. Ghaemi S.N. Bipolar disorder and antidepressants: an ongoing controversy // Primary Psychiatry. – 2001. – 8 (2). – Р. 28–34.
6. Rowland T.A., Marwaha S. Epidemiology and risk factors for bipolar disorder // Ther. Adv. Psychopharmacol. – 2018. – 8 (9). – Р. 251-269. Published 2018 Apr 26. doi:10.1177/2045125318769235
7. Акжигитов Р.Г., Яковлев А.Ю. К вопросу о диагностике расстройств биполярногоспектра // Обозрение психиатрии и медицинской психологии. – 2011. – 1. – С. 41-45.
8. Тювина Н.А., Смирнова В.Н. Биполярное аффективное расстройство: особенности течения и поддерживающая фармакотерапия // Неврология, нейропсихиатрия, психосоматика. – 2013. – 5 (1). – С. 87-95.
9. Тювина Н.А., Столярова А.Е., Смирнова В.Н. Биполярное аффективное расстройство: гендерные особенности течения и терапии // Журнал неврологии и психиатрии им. С.С.Корсакова. – 2019. – 119 (12). – С. 162-169. https://doi.org/10.17116/jnevro2019119121162
10. Frye M.A. ,Altshuler L.L., McElroy S.L. et al. Gender differences in prevalence, risk, and clinical correlates of alcoholism comorbidity in bipolar disorder //Am. J. Psychiatry. – 2003. – 160 (5). – Р. 883-889.https://doi.org/10.1176/appi.ajp.160.5.88
11. Мосолов С.Н., Федорова Е.Ю. Риск развития сердечно-сосудистых заболеваний при биполярном расстройстве. Клинико-социальные факторы. // Терапевтический архив. – 2021. – 93 (12). – Р. 1556–1561. doi:10.26442/00403660.2021.12.201175
12. Sultan A.A., Hird M.A., Dimick M.K. et al. Cannabis use and resting state functional connectivity in adolescent bipolar disorder // J. Psychiatry Neurosci. – 2021. – 46 (5). – Р. E559-E567. doi:10.1503/jpn.200228
13. Soreca I., Fagiolini A., Frank E. et al. Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder. // J. Psychiatr. Res. – 2008. – 42. – Р. 956–961.
14. Roshanaei-Moghaddam B., Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review // Psychiatr. Serv. – 2009. – 60. – Р. 147–156.
15. McElroy M. Obesity in patients with severe mental illness: overview and management // Journal of Clinical Psychiatry. – 2009. – 70 (3). – Р. 12¬21.
16. Fagiolini A., Frank E., Scott J.A. et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians // Bipolar Disord. – 2005. – 7. – Р. 424–430.
17. Ruzickova M., Slaney C., Garnham J. et al. Clinical features of bipolar disorder with and without comorbid diabetes mellitus // Can. J. Psychiatry. – 2003. – 48. – Р. 458–461.
18. Marques T.R. Dopamine, striatum, antipsychotics, and questions about weight gain // JAMA Psychiatry. – 2016. – 73. – Р. 107–108.
19. Elmslie J.L., Silverstone J.T., Mann J.I. et al. Prevalence of overweight and obesity in bipolar patients // J. Clin. Psychiatry. – 2000. – 61. – Р. 179–184.
20. McElroy S.L., Frye M.A., Suppes T. et al. Correlates of overweight and obesity in 644 patients with bipolar disorder // J. Clin. Psychiatry. – 2002. – 63. – Р. 207–213.
21. Maina G., Salvi V., Vitalucci A. et al. Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder // J. Affect. Disord. – 2008. – 110. – Р. 149–155.
22. Correll C.U., Frederickson A.M., Kane J.M. et al. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics // Bipolar Disord. – 2008. – 10. – Р. 788–797.
23. Petri E., Bacci O., Barbuti M. et al. Obesity in patients with major depression is related to bipolarity and mixed features: evidence from the BRIDGE-II-MIX study // Bipolar Disord. – 2017. – 378 (12). – Р. 1561-1568. doi:10.1111/bdi.12519
24. Fagiolini A., Kupfer D.J., Houck P.R. et al. Obesity as a correlate of outcome in patients with bipolar I disorder // Am. J. Psychiatry. – 2003. – 160. – Р. 112–117.
25. Beyer J., Kuchibhatla M., Gersing K. et al. Medical comorbidity in a bipolar outpatient clinical population // Neuropsychopharmacol. – 2005. – 30. – Р. 401–404.
26. McIntyre R.S., Konarski J.Z., Soczynska J.K. et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization // Psychiatr. Serv. – 2006. – 57. – Р. 1140–1144.
27. Thompson W.K., Kupfer D.J., Fagiolini A. et al. Prevalence and clinical correlates of medical comorbidities in patients with bipolar I disorder: analysis of acute-phase data from a randomized controlled trial // J. Clin. Psychiatry. – 2006. – 67. – Р. 783–788.
28. Kemp D.E., Gao K., Ganocy S.J. et al. Medical and substance use comorbidity in bipolar disorder // J. Affect. Disord. – 2009. – 116. – Р. 64–69.
29. Pirraglia P.A., Biswas K., Kilbourne A.M. et al. A prospective study of the impact of comorbid medical disease on bipolar disorder outcomes // J. Affect. Disord. – 2009. – 115. – Р. 355–359.
30. Soreca I., Frank E., Kupfer D.J. The phenomenology of bipolar disorder: what drives the high rate of medical burden and determines long-term prognosis // Depress. Anxiety. – 2009. – 26. – Р. 73–82.
31. Chakrabarti S. Thyroid functions and bipolar affective disorder // J. Thyroid Res. – 2011. – Р. 306-367. doi:10.4061/2011/30636
32. Soreca I., Fagiolini A., Frank E. et al. Chronotype and body composition in bipolar disorder // Chronobiol. Int. – 2009. – 26. – Р. 780–788.
33. Fleet-Michaliszyn S.B., Soreca I., Otto A.D. et al. A prospective observational study of obesity, body composition, and insulin resistance in 18 women with bipolar disorder and 17 matched control subjects // J. Clin. Psychiatry. – 2008. – 69. – Р. 1892–1900.
34. McIntyre R.S., Soczynska J.K., Konarski J.Z. et al. Should depressive syndromes be reclassified as “metabolic syndrome type II?” // Ann. Clin. Psychiatry. – 2007. – 19. – Р. 257–264.
35. McIntyre R.S., Rasgon N.L., Kemp D.E. et al. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap // Curr. Diab. Rep. – 2009. – 9. – Р. 51–59.
36. Mosolov S.N. Polysomnographic study in rapid-cyclers with bipolar affective disorder // Homeostasis in Health and Disease. – 1995. – Vol. 36. – № S1. – P. 95-96.
37. Sharafkhaneh A., Giray N., Richardson P. et al. Association of psychiatric disorders and sleep apnea in a large cohort // Sleep. – 2005. – 28. – Р. 1405–1411.
38. Kawahara S., Akashiba T., Akahoshi T. et al. Nasal CPAP improves the quality of life and lessens the depressive symptoms in patients with obstructive sleep apnea syndrome // Intern. Med. – 2005. – 44. – Р. 422–427.
39. Kapczinski F., Vieta E., Andreazza A.C. et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment // Neurosci. Biobehav. Rev. – 2008. – 32. – Р. 675–692.
40. Sathya A., Radhika R., Mahadevan S. et al. Mania as a presentation of primary hypothyroidism // Singapore Medical Journal. – 2009. – 50 (2). – Р. e65–e67.
41. Thomsen A.F., Kessing L.V. Increased risk of hyperthyroidism among patients hospitalized with bipolar disorder // Bipolar Disorders. – 2005. – 7 (4). – Р. 351–357
42. Stranges E.M., Houchens R.L., Mark T.L. et al. Patients with bipolar disorder at higher risk for wide range of physical comorbidities // Thomson Reuters. – 2009. http://home.thomsonhealthcare.com/research/treemaps.
43. Azorin J.M., Kaladjian A., Adida M. et al. Factors associated with rapid cycling in bipolar I manic patients: findings from a French national study // CNS Spectrums. – 2008. – 13 (9). – Р. 780–787.
44. Goyal M., Yadav K.S., Solanki R.K. A study of thyroid profile in patients suffering from the first episode of mania. A cross-sectional study // Indian Journal of Psychiatry. – Jul–Aug 2021. – Vol. 63. – Issue 4. – Р. 395-399. doi: 10.4103/psychiatry.IndianJPsychiatry_33_20
45. McIntyre R.S., Konarski J.Z., Soczynska J.K. et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization // Psychiatric Services. – 2006. – 57 (8). – Р. 1140–1144.
46. Kilbourne A.M., Cornelius J.R., Han X. et al. Burden of general medical conditions among individuals with bipolar disorder // BipolarDisorders. – 2004. – 6 (5). – Р. 368–373.
47. Горобец Л.Н. Ермолаева Л.Г., Литвинов А.В. Соотношение клинических и гормональных показателей гипоталамо-гипофизарно-тиреоидной оси у женщин с параноидной шизофренией и шизоаффективным расстройством в процессе терапии атипичными нейролептиками // Сибирский вестник психиатрии и наркологии. – 2006. – № 2 (40). – С. 12-16.
48. Горобец Л.Н. Особенности влияния терапии атипичными антипсихотиками на функциональное состояние гипоталамо-гипофизарно-тиреоидной оси // Российский психиатрический журнал. – 2006. – № 6. – С. 68-75.
49. Li C., Lai J., Huang T. et al. Thyroid functions in patients with bipolar disorder and the impact of quetiapine monotherapy: a retrospective, naturalistic study // Neuropsychiatr. Dis. Treat. – 2019. – 15. – С. 2285-2290. doi:10.2147/NDT.S1966
50. van Enkhuizen J., Janowsky D.S., Olivier B. et al. The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited // Eur. J. Pharmacol. – 2015. – 753. – Р. 114-126. doi:10.1016/j.ejphar.2014.05.063
51. Salvi V., Fagiolini A., Swartz H.A. et al.The use of antidepressants in bipolar disorder // J. Clin. Psychiatry. – 2008. – 69. – Р. 1307–1318.
52. Cousins D.A., Butts K., Young A.H. The role of dopamine in bipolar disorder // Bipolar disorders. – 2009. – 11. – Р. 787–806.
53. Wang J., Michelhaugh S.K., Bannon M.J. Valproate robustly increases Sp transcription factor-mediated expression of the dopamine transporter gene within dopamine cells // Eur. J. Neurosci. – 2007. – 25. – Р. 1982–1986.
54. Scaini G., Valvassori S.S., Diaz A.P. et al. Neurobiology of bipolar disorders: a review of genetic components, signaling pathways, biochemical changes, and neuroimaging findings // Braz. J. Psychiatry. – 2020. – 42 (5). – Р. 536-551. doi:10.1590/1516-4446-2019-0732
55. Мосолов С.Н., Федорова Е.Ю. Риск развития сердечно-сосудистых заболеваний при биполярном расстройстве. Биологические факторы и терапия. // Терапевтический архив. 2022;94(4):579–583. DOI: 10.26442/00403660.2022.04.201455
56. Faurholt-Jepsen M., Frøkjær V.G., Nasser A. et al.Associations between the cortisol awakening response and patient-evaluated stress and mood instability in patients with bipolar disorder: an exploratory study // Int. J. Bipolar Disord. – 2021. – 9 (1). – р. 8. doi:10.1186/s40345-020-00214-0
57. Kiss B., Laszlovszky I., Horváth A. et al. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. Neurochemical characterisation of RG-15 // Arch. Pharmacol. – 2008. – 378. – Р. 515–528.
58. Cho D.I., Zheng M., Kim K.M. Current perspectives on the selective regulation of dopamine D(2) and D(3) receptors // Arch. Pharm. Res. – 2010. – 33. – Р. 1521– 1538.
59. Adham N., Samoriski G., Gao Y. et al. Cariprazine (RGH-188), a potential antipsychotic with dopamine D3/D2 functional antagonist properties, attenuates manic-like behaviors in animal models // World J. Biol. Psychiatry. –2009. – 10 (Suppl. 1). – р. 304.
60. Gyertyán I., Kiss B., Sághy K. et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents // Neurochem. Int. – 2011. – 59. – Р. 925–935
61. Duman R.S., Duric V., Banasr M. et al. Cariprazine exhibits dopamine D3 receptor-dependent antidepressant-like activity in the chronic unpredictable stress model of anhedonia // Neuropsychopharmacology. – 2012. – 38 (Suppl. 1). – р. S84.
62. Durgam S., Starace A., Li D., Migliore R., Ruth A., Németh G., Laszlovszky I. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial // Bipolar. Disord. – 2015. – 17. – Р. 63-75.
63. Herman A., El Mansari M., Adham N. et al. Involvement of 5-HT1A and 5-HT2A receptors but not α2-adrenoceptors in the acute electrophysiological effects of cariprazine in the rat brain in vivo // Mol. Pharmacol. – 2018. – 94. – Р. 1363-1370.
64. Duric V., Banasr M., Franklin T. et al.Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model // Int. J. Neuropsychopharmacol. – 2017. – 20. – Р. 788-796.
65. Stahl S.M., Laredo S., Morrissette D.A. Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data // Ther. Adv. Psychopharmacol. – 2020. – Feb 12. – 10. –2045125320905752. doi: 10.1177/2045125320905752
66. Patel M., Jain R., Tohen M. et al. Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies // Int. Clin. Psychopharmacol. – 2021. – Mar 1. 36 (2). –Р. 76-83. doi: 10.1097/YIC.0000000000000344
67. Антонович Б.А. Применение карипразина при биполярном аффективном расстройстве // Современная терапия психических расстройств. –2021. – №1. – С. 34-43. doi:10.21265/PSYPH.2021.46.92.005
68. Earley W.R., Burgess M.V., Khan B. et al. Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study // Bipolar Disord. – 2020. – 22 (4). – Р. 372-384. doi:10.1111/bdi.12852
69. Durgam S., Earley W., Lu K. et al. Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis // Int. J. Clin. Pract. – 2017. – 71 (12). – р. e13037. doi:10.1111/ijcp.13037
70. Горобец Л.Н., Литвинов А.В. Карипразин: нейроэндокринные и метаболические аспекты переносимости у больных с психическими расстройствами // Современная терапия психических расстройств. – 2020. –№3. – С. 19-27.
71. Leucht S. et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors // Am. J. Psychiatry. – 2017. – 174. – Р. 927–942.
72. Ketter T.A., Sachs G.S., Durgam S. et al. The safety and tolerability of cariprazine in patients with bipolar I disorder: A 16-week open-label study // J. Affect. Disord. – 2018. – 225. – С. 350-356.
73. Доровских И.В., Павлова Т.А., Шайдеггер Ю.М. Карипразин – современный антипсихотик с благоприятным нейроэндокринным профилем // Формулы Фармации. – 2020. – Т. 2. №3. – С. 58-63. doi: 10.17816/phf46072
74. Durgam S., Starace A., Li D. et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial // Bipolar. Disord. – 2015. – 17. – С. 63-75.
75. Campbell R.H., Diduch M., Gardner K.N. et al. Review of cariprazine in management of psychiatric illness // Ment. Health Clin. – 2018. – 7 (5). – Р. 221-229. doi:10.9740/mhc.2017.09.221